GPC3 and hepatocellular carcinoma: Additionally, CStone Pharmaceuticals’ GPC3-targeted CAR-T therapy has yielded notable outcomes in advanced hepatocellular carcinoma (HCC), with two patients remaining tumor-free for over seven years (17).